Nordea Investment Management AB Grows Stock Holdings in Edwards Lifesciences Co. (NYSE:EW)

Nordea Investment Management AB increased its holdings in shares of Edwards Lifesciences Co. (NYSE:EW - Free Report) by 34.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 4,057,013 shares of the medical research company's stock after purchasing an additional 1,043,484 shares during the quarter. Nordea Investment Management AB owned approximately 0.69% of Edwards Lifesciences worth $301,355,000 at the end of the most recent quarter.

Several other institutional investors also recently added to or reduced their stakes in the company. Wellington Management Group LLP increased its position in Edwards Lifesciences by 86.3% during the third quarter. Wellington Management Group LLP now owns 31,532,725 shares of the medical research company's stock worth $2,080,845,000 after buying an additional 14,610,123 shares during the period. State Street Corp increased its position in Edwards Lifesciences by 1.0% during the third quarter. State Street Corp now owns 26,265,633 shares of the medical research company's stock worth $1,733,270,000 after buying an additional 256,538 shares during the period. Geode Capital Management LLC increased its holdings in shares of Edwards Lifesciences by 2.2% in the third quarter. Geode Capital Management LLC now owns 13,521,147 shares of the medical research company's stock valued at $889,050,000 after purchasing an additional 284,918 shares during the period. Fisher Asset Management LLC increased its holdings in shares of Edwards Lifesciences by 9.8% in the third quarter. Fisher Asset Management LLC now owns 9,078,311 shares of the medical research company's stock valued at $599,078,000 after purchasing an additional 806,705 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in shares of Edwards Lifesciences by 1.0% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 6,005,789 shares of the medical research company's stock worth $396,322,000 after purchasing an additional 61,275 shares during the last quarter. Institutional investors and hedge funds own 79.46% of the company's stock.

Insider Activity

In related news, VP Donald E. Bobo, Jr. sold 5,000 shares of the company's stock in a transaction that occurred on Tuesday, October 15th. The shares were sold at an average price of $69.51, for a total transaction of $347,550.00. Following the completion of the transaction, the vice president now owns 46,936 shares of the company's stock, valued at approximately $3,262,521.36. This represents a 9.63 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Larry L. Wood sold 25,000 shares of the company's stock in a transaction that occurred on Tuesday, November 5th. The stock was sold at an average price of $65.91, for a total transaction of $1,647,750.00. Following the transaction, the insider now directly owns 198,526 shares of the company's stock, valued at $13,084,848.66. This trade represents a 11.18 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 37,500 shares of company stock valued at $2,508,350 over the last 90 days. Insiders own 1.29% of the company's stock.

Edwards Lifesciences Price Performance

EW traded down $0.36 during midday trading on Monday, reaching $73.55. 4,102,465 shares of the company's stock were exchanged, compared to its average volume of 4,549,222. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89. The stock has a market capitalization of $43.38 billion, a PE ratio of 10.61, a P/E/G ratio of 3.63 and a beta of 1.11. The business's 50-day moving average price is $71.08 and its 200 day moving average price is $72.51. Edwards Lifesciences Co. has a 1-year low of $58.93 and a 1-year high of $96.12.

Edwards Lifesciences (NYSE:EW - Get Free Report) last announced its earnings results on Thursday, October 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $0.67. The company had revenue of $1.35 billion during the quarter, compared to analysts' expectations of $1.57 billion. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. The firm's quarterly revenue was up 8.9% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.59 earnings per share. As a group, equities analysts anticipate that Edwards Lifesciences Co. will post 2.56 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

EW has been the topic of several recent research reports. Evercore ISI dropped their price objective on shares of Edwards Lifesciences from $76.00 to $70.00 and set an "in-line" rating on the stock in a research note on Tuesday, October 1st. Barclays lifted their target price on shares of Edwards Lifesciences from $85.00 to $88.00 and gave the company an "overweight" rating in a report on Monday, December 2nd. The Goldman Sachs Group lifted their target price on shares of Edwards Lifesciences from $81.00 to $90.00 and gave the company a "buy" rating in a report on Thursday, December 5th. Piper Sandler lowered their target price on shares of Edwards Lifesciences from $73.00 to $70.00 and set a "neutral" rating on the stock in a report on Friday, October 25th. Finally, Oppenheimer reaffirmed an "outperform" rating and issued a $90.00 target price on shares of Edwards Lifesciences in a report on Thursday, September 12th. Sixteen equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company's stock. According to MarketBeat.com, Edwards Lifesciences has an average rating of "Hold" and an average price target of $79.40.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.